Read by QxMD icon Read

JING's NSF 2014

shared collection
6 papers 0 to 25 followers Myd88 breast cancer
By Jing Fan I am a endocrine surgeon, majoring breast and thyroid disease.
Fang-Jing Ma, Zhe-Bin Liu, Xin Hu, Hong Ling, Shan Li, Jiong Wu, Zhi-Ming Shao
PURPOSE: Breast cancer remains a major cause of death in women worldwide, and tumor metastasis is the leading cause of death in breast cancer patients after conventional treatment. Chronic inflammation is often related to the occurrence and growth of various malignancies. This study evaluated the prognosis of breast cancer patients based on contributors to the innate immune response: myeloid differentiation primary response 88 (MyD88) and Toll-like receptor 4 (TLR4). METHODS: We analyzed data from 205 breast invasive ductal carcinoma (IDC) patients who were treated at the Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, from 2002 to 2006...
2014: PloS One
Ferenc A Scheeren, Angera H Kuo, Linda J van Weele, Shang Cai, Iris Glykofridis, Shaheen S Sikandar, Maider Zabala, Dalong Qian, Jessica S Lam, Darius Johnston, Jens P Volkmer, Debashis Sahoo, Matt van de Rijn, Frederick M Dirbas, George Somlo, Tomer Kalisky, Michael E Rothenberg, Stephen R Quake, Michael F Clarke
It has been postulated that there is a link between inflammation and cancer. Here we describe a role for cell-intrinsic toll-like receptor-2 (TLR2; which is involved in inflammatory response) signalling in normal intestinal and mammary epithelial cells and oncogenesis. The downstream effectors of TLR2 are expressed by normal intestinal and mammary epithelia, including the stem/progenitor cells. Deletion of MYD88 or TLR2 in the intestinal epithelium markedly reduces DSS-induced colitis regeneration and spontaneous tumour development in mice...
December 2014: Nature Cell Biology
Krishan K Thakur, Nityanand B Bolshette, Cristiana Trandafir, Vinayak S Jamdade, Alexandru Istrate, Ranadeep Gogoi, Andrei Cucuianu
Multiple myeloma (MM) is a hematologic malignancy characterized as an abnormal proliferation and invasion of plasma cells into the bone marrow. Toll-like receptors (ТLRs) connect the innate and adaptive immune responses and represent a significant and potentially linking element between inflammation and cancer. When TLRs bind to their ligands, they trigger two major signaling pathways such that both share overlapping downstream signals: one is a myeloid differentiation primary response 88 (MyD88)-dependent production and activation of nuclear factor-κB, whereas the other is a MyD88-independent production of type-I interferon...
March 2015: Experimental Hematology
Jean-Laurent Casanova, Laurent Abel, Lluis Quintana-Murci
Toll-like receptors (TLRs) and interleukin-1 receptors (IL-1Rs) have TIR intracellular domains that engage two main signaling pathways, via the TIR-containing adaptors MyD88 (which is not used by TLR3) and TRIF (which is used only by TLR3 and TLR4). Extensive studies in inbred mice in various experimental settings have attributed key roles in immunity to TLR- and IL-1R-mediated responses, but what contribution do human TLRs and IL-1Rs actually make to host defense in the natural setting? Evolutionary genetic studies have shown that human intracellular TLRs have evolved under stronger purifying selection than surface-expressed TLRs, for which the frequency of missense and nonsense alleles is high in the general population...
2011: Annual Review of Immunology
Ream Langhe, Lucy Norris, Feras Abu Saadeh, Gordon Blackshields, Rachel Varley, Ashling Harrison, Noreen Gleeson, Cathy Spillane, Cara Martin, Dearbhaile M O'Donnell, Tom D'Arcy, John O'Leary, Sharon O'Toole
Ovarian cancer is the seventh most common cancer in women and the most frequent cause of gynaecological malignancy-related mortality in women. Currently, no standardized reliable screening test exists. MicroRNA profiling has allowed the identification of signatures associated with diagnosis, prognosis and response to treatment of human tumours. The aim of this study was to determine if a microRNA signature could distinguish between malignant and benign ovarian disease. A training set of 5 serous ovarian carcinomas and 5 benign serous cystadenomas were selected for the initial experiments...
January 28, 2015: Cancer Letters
Angera H Kuo, Ferenc A Scheeren
No abstract text is available yet for this article.
2014: Cell Cycle
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"